3%) af myeloplastiske syndromer (MDS) eller leukæmi hos patienter med SCN, der fik filgrastim.
There was a low frequency (approximately 3%) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim.